Advertisement
Screener

SELLAS Life Sciences Group, Inc. (SLS) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

1.5 / 5 stars · 20/67 Roast Me

SELLAS Life Sciences Group, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

SELLAS Life Sciences Group, Inc. (SLS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-11

  • SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
  • SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
  • SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
  • SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-06-30 was 0.00%.
  • SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2026-06-300.00%
10-Q · filed 2026-08-11
2026-03-310.00%
10-Q · filed 2026-05-12
2025-12-310.00%
10-K · filed 2026-03-19
2025-09-300.00%
10-Q · filed 2025-11-12
2025-06-300.00%
10-Q · filed 2026-08-11
2025-03-310.00%
10-Q · filed 2026-05-12
2024-12-310.00%
10-K · filed 2026-03-19
2024-09-300.00%
10-Q · filed 2025-11-12
2024-06-300.00%
10-Q · filed 2025-08-12
2024-03-310.00%
10-Q · filed 2025-05-13
2023-12-310.00%
10-K · filed 2025-03-20
2023-09-300.00%
10-Q · filed 2024-11-13
2023-06-300.00%
10-Q · filed 2024-08-13
0.00%
10-Q · filed 2024-08-13
2023-03-310.00%
10-Q · filed 2024-05-14
2022-12-310.00%
10-K · filed 2024-03-28
2022-09-300.00%
10-Q · filed 2023-11-09
0.00%
10-Q · filed 2023-11-09
2022-06-300.00%
10-Q · filed 2023-08-10
0.00%
10-Q · filed 2023-08-10
2022-03-310.00%
10-Q · filed 2023-05-11
2021-12-310.00%
10-K · filed 2023-03-16
2021-09-300.00%
10-Q · filed 2022-11-14
0.00%
10-Q · filed 2022-11-14
2021-06-300.00%
10-Q · filed 2022-08-11
0.00%
10-Q · filed 2022-08-11
2021-03-310.00%
10-Q · filed 2022-05-12
2020-12-310.00%
10-K · filed 2022-03-31
2020-09-300.00%
10-Q · filed 2021-11-12
2020-06-300.00%
10-Q · filed 2021-08-12
0.00%
10-Q · filed 2021-08-12
2020-03-310.00%
10-Q · filed 2021-05-13
2019-12-310.00%
10-K · filed 2021-03-23
2019-09-300.00%
10-Q · filed 2020-11-13
2019-06-300.00%
10-Q · filed 2020-08-13
0.00%
10-Q · filed 2020-08-13
2019-03-310.00%
10-Q · filed 2020-05-14
2018-12-310.00%
10-K · filed 2020-03-13
2018-09-300.00%
10-Q · filed 2019-11-14
2018-06-300.00%
10-Q · filed 2018-08-14
0.00%
10-Q · filed 2018-08-14
2018-03-310.00%
10-Q · filed 2019-05-15
2017-09-300.00%
10-Q · filed 2017-11-09
0.00%
10-Q · filed 2019-08-14
2017-06-300.00%
10-Q · filed 2017-08-14
0.00%
10-Q · filed 2017-08-14
2017-03-310.00%
10-Q · filed 2017-05-10
2016-12-310.00%
10-K · filed 2017-03-15
2016-09-300.00%
10-Q · filed 2017-11-09
0.00%
10-Q · filed 2017-11-09
2016-06-300.00%
10-Q · filed 2017-08-14
0.00%
10-Q · filed 2017-08-14
2016-03-310.00%
10-Q · filed 2017-05-10
2015-12-310.00%
10-K · filed 2017-03-15
2015-09-300.00%
10-Q · filed 2016-11-09
0.00%
10-Q · filed 2016-11-09
2015-06-300.00%
10-Q · filed 2016-08-09
0.00%
10-Q · filed 2016-08-09
2015-03-310.00%
10-Q · filed 2016-05-10
2014-12-310.00%
10-K · filed 2017-03-15
2014-09-300.00%
10-Q · filed 2015-11-09
0.00%
10-Q · filed 2015-11-09
2014-06-300.00%
10-Q · filed 2015-08-06
0.00%
10-Q · filed 2015-08-06
2014-03-310.00%
10-Q · filed 2015-05-07
2013-12-310.00%
10-K/A · filed 2016-04-15
2013-09-300.00%
10-Q/A · filed 2013-11-07
0.00%
10-Q · filed 2014-11-05
2013-06-300.00%
10-Q · filed 2013-08-09
0.00%
10-Q · filed 2014-08-11
2013-03-310.00%
10-Q · filed 2014-05-06
2012-12-310.00%
8-K · filed 2015-12-04
2012-09-300.00%
10-Q · filed 2012-11-13
0.00%
10-Q/A · filed 2013-11-07
2012-06-300.00%
10-Q · filed 2012-08-14
0.00%
10-Q · filed 2013-08-09
2012-03-310.00%
10-Q · filed 2014-11-05
2011-12-310.00%
10-K · filed 2013-03-12
2011-09-300.00%
10-Q · filed 2012-11-13
0.00%
10-Q · filed 2012-11-13
2011-06-300.00%
10-Q · filed 2012-08-14
0.00%
10-Q · filed 2012-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Immunome Inc. (IMNM)United States$2.538B-9.45
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Zai Lab Ltd (ZLAB)$2.241B-113.34